Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases.
Viral aerosols
experimental inoculation
human challenge model
influenza symptomatology
influenza transmission
propensity scores
viral shedding
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
15
05
2020
revised:
08
07
2020
accepted:
09
07
2020
pubmed:
25
7
2020
medline:
26
11
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
It has long been known that nasal inoculation with influenza A virus produces asymptomatic to febrile infections. Uncertainty persists about whether these infections are sufficiently similar to natural infections for studying human-to-human transmission. We compared influenza A viral aerosol shedding from volunteers nasally inoculated with A/Wisconsin/2005 (H3N2) and college community adults naturally infected with influenza A/H3N2 (2012-2013), selected for influenza-like illness with objectively measured fever or a positive Quidel QuickVue A&B test. Propensity scores were used to control for differences in symptom presentation observed between experimentally and naturally infected groups. Eleven (28%) experimental and 71 (86%) natural cases shed into fine particle aerosols (P < .001). The geometric mean (geometric standard deviation) for viral positive fine aerosol samples from experimental and natural cases was 5.1E + 3 (4.72) and 3.9E + 4 (15.12) RNA copies/half hour, respectively. The 95th percentile shedding rate was 2.4 log Due to selection bias, the natural and experimental infections had limited symptom severity distributional overlap precluding valid, propensity score-adjusted comparison. Relative to the symptomatic naturally infected cases, where high aerosol shedders were found, experimental cases did not produce high aerosol shedders. Studying the frequency of aerosol shedding at the highest observed levels in natural infections without selection on symptoms or fever would support helpful comparisons.
Sections du résumé
BACKGROUND
It has long been known that nasal inoculation with influenza A virus produces asymptomatic to febrile infections. Uncertainty persists about whether these infections are sufficiently similar to natural infections for studying human-to-human transmission.
METHODS
We compared influenza A viral aerosol shedding from volunteers nasally inoculated with A/Wisconsin/2005 (H3N2) and college community adults naturally infected with influenza A/H3N2 (2012-2013), selected for influenza-like illness with objectively measured fever or a positive Quidel QuickVue A&B test. Propensity scores were used to control for differences in symptom presentation observed between experimentally and naturally infected groups.
RESULTS
Eleven (28%) experimental and 71 (86%) natural cases shed into fine particle aerosols (P < .001). The geometric mean (geometric standard deviation) for viral positive fine aerosol samples from experimental and natural cases was 5.1E + 3 (4.72) and 3.9E + 4 (15.12) RNA copies/half hour, respectively. The 95th percentile shedding rate was 2.4 log
CONCLUSIONS
Due to selection bias, the natural and experimental infections had limited symptom severity distributional overlap precluding valid, propensity score-adjusted comparison. Relative to the symptomatic naturally infected cases, where high aerosol shedders were found, experimental cases did not produce high aerosol shedders. Studying the frequency of aerosol shedding at the highest observed levels in natural infections without selection on symptoms or fever would support helpful comparisons.
Identifiants
pubmed: 32705798
doi: 10.1111/irv.12790
pmc: PMC7767952
doi:
Substances chimiques
Aerosols
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-163Subventions
Organisme : NCIRD CDC HHS
ID : U01 IP000497
Pays : United States
Informations de copyright
© 2020 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
PLoS One. 2016 May 06;11(5):e0154418
pubmed: 27153194
Nat Commun. 2019 Apr 10;10(1):1660
pubmed: 30971703
PLoS Pathog. 2020 Jul 13;16(7):e1008704
pubmed: 32658939
J R Soc Interface. 2009 Dec 6;6 Suppl 6:S783-90
pubmed: 19773292
Epidemiology. 2015 Nov;26(6):862-72
pubmed: 26133025
Arch Intern Med. 2002 Sep 9;162(16):1842-8
pubmed: 12196082
BMC Infect Dis. 2019 Jan 31;19(1):101
pubmed: 30704406
Aerosol Sci Technol. 2013 Jan 1;47(4):444-451
pubmed: 23418400
Epidemiol Infect. 2017 Mar;145(4):723-727
pubmed: 27916020
Nat Commun. 2013;4:1935
pubmed: 23736803
Clin Infect Dis. 2016 Feb 15;62(4):431-437
pubmed: 26518469
J Immunol. 1946 Feb;52:145-65
pubmed: 21018818
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1081-1086
pubmed: 29348203
Front Cell Infect Microbiol. 2012 Nov 29;2:150
pubmed: 23226686
Influenza Other Respir Viruses. 2021 Jan;15(1):154-163
pubmed: 32705798
J Infect Dis. 2013 Apr 15;207(8):1281-5
pubmed: 23382573
Lancet Infect Dis. 2011 Nov;11(11):879-86
pubmed: 21798808
Lancet Respir Med. 2014 Jun;2(6):445-54
pubmed: 24717637
Br J Gen Pract. 2004 Sep;54(506):684-9
pubmed: 15353055
Proc Soc Exp Biol Med. 1966 Jul;122(3):800-4
pubmed: 5918954
J Med Virol. 1979;3(3):177-88
pubmed: 479857
J Infect Dis. 2015 Nov 1;212(9):1420-8
pubmed: 25883385
J Infect Dis. 2010 May 15;201(10):1509-16
pubmed: 20377412
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677